Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension

Health and Quality of Life Outcomes

Marco Soro¹  John E Brazier³  Julian F Guest²  Uwe Haag⁴  Pedro Marques da Silva⁵ 

[1] Health Economics & Outcomes Research Department, Daiichi-Sankyo Europe, Munich, Germany;Faculty of Life Sciences and Medicine, King’s College, London, UK;Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK;HaaPACS GmbH, Schriesheim, Germany;Arterial Investigation Unit, Medicine 4, Santa Marta’s Hospital, CHLC, Lisbon, Portugal

关键词: Pill burden;    Hypertension;    HRQoL;    Adherence;    Olmesartan;   

Others  :  1133800
DOI  :  10.1186/s12955-015-0216-6

 received in 2014-09-01, accepted in 2015-01-27,  发布年份 2015

【 摘 要 】

Background

A post-hoc analysis was performed on the data from a 54 weeks phase III study (ClinicalTrials.gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ), using the MINICHAL and EQ-5D instruments.

Methods

Descriptive statistics were used to assess blood pressure and HRQoL scores over the study period. Analysis of covariance (ANCOVA) was used to identify those factors that could possibly have influenced HRQoL. Linear regression was used to assess the relationship between changes in blood pressure and HRQoL scores.

Results

Patients’ baseline MINICHAL mood and somatic domains scores were 5.5 and 2.6. Over the study period HRQoL improved as both MINICHAL scores decreased by 31-33%. Patients’ baseline EQ-5D index and VAS scores were 0.9 and 73.4 respectively, increasing by 6% and 12% over the study period. Patients’ QALY gain over the 54 weeks study period was estimated to be 0.029 QALYs. The ANCOVA showed that changes in patients’ HRQoL was likely to have been influenced by patients’ achievement of blood pressure control, the amount of concomitant medication and patients’ last used dosage strength of antihypertensive. Linear regression showed that blood pressure improvement may have been associated with improved HRQoL.

Conclusions

This study showed that OLM/AML/HCTZ reduced blood pressure and significantly increased blood pressure control whilst improving patients’ HRQoL. Achieving blood pressure control, amount of concomitant medication and dosage strength of antihypertensive impacted on patients’ HRQoL.

【 授权许可】

   
2015 Marques da Silva et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J. 2014. ([Epub ahead of print]). Available from: http://www.ncbi.nlm.nih.gov/pubmed/24917639.
• [2]Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SCFF: Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2011, 29(2):179-88.
• [3]Zygmuntowicz M, Owczarek A, Elibol A, Chudek J: Comorbidities and the quality of life in hypertensive patients. Pol Arch Med Wewnętrznej 2012, 122(7–8):333-40.
• [4]Wang R, Zhao Y, He X, Ma X, Yan X, Sun Y, et al.: Impact of hypertension on health-related quality of life in a population-based study in Shanghai. China Pub Health 2009, 123:534-9.
• [5]Aydemir O, Ozdemir C, Koroglu E: The impact of co-morbid conditions on the SF-36: A primary-care-based study among hypertensives. Arch Med Res 2005, 36:136-41.
• [6]Erickson SR, Williams BC, Gruppen LD: Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls. J Hum Hypertens 2001, 15:539-48.
• [7]Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.: Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). J Hypertens 2007, 25(6):1105-87.
• [8]Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al.: Reappraisal of european guidelines on hypertension management: a european society of hypertension task force document. J Hypertens 2009, 27(11):2121-58.
• [9]Oparil S, Melino M, Lee J, Fernandez V, Heyrman R: Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010, 32:1252-69.
• [10]Volpe M, Christian Rump L, Ammentorp B, Laeis P: Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012, 32(10):1.
• [11]Volpe M, de la Sierra A, Ammentorp B, Laeis P: Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther 2014, 31(5):561-74.
• [12]EuroQol. EQ-5D. Available from: http://www.euroqol.org/.
• [13]Badia X, Roca-Cusachs A, Dalfo A, Gascon G, Abellan J, Lahoz R, Varela C, Velasco O: Validation of the short form of the Spanish Hypertension Quality of Life Questionnaire (MINICHAL). Clin Ther 2002, 24(12):2137-54.
• [14]Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-108.
• [15]Roca-cusachs À, Badia X, Dalfó A, Gascón G, De Bienestar Í: Relación entre variables clínicas y terapéuticas y calidad de vida relacionada con la salud en pacientes con hipertensión arterial. Estudio MINICHAL. Med Clin 2003, 121(1):12-7.
• [16]Schulz RB, Rossignoli P, Correr CJ, Fernández-Llimós FTP: Validation of the short form of the spanish hypertension quality of life questionnaire ( MINICHAL) for Portuguese ( Brazil). Arq Bras Cardiol 2008, 90(2):127-31.
• [17]Carvalho MA, Silva IB, Ramos SB, Coelho LF, Goncalves ID, Figueiredo Neto JA, et al.: Quality of life of hypertensive patients and comparison of two instruments of HRQOL measure. Arq Bras Cardiol 2012, 98(5):442-50.
• [18]Roca-Cusachs A, Dalfó A, Badia X, Arístegui I, Roset M: Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens 2001, 19(10):1913-9.
• [19]Youssef RM, Moubarak II, Kamel MI: Factors affecting the quality of life of hypertensive patients. East Mediterr Heal J 2005, 11(1–2):109-18.
• [20]Santos L, Chaves C, Andrade A, Duarte J: The influence of stress on the quality of life of hypertensive patients. Procedia - Soc Behav Sci Elsevier B V 2014, 113:16-25.
• [21]Panjabi S, Lacey M, Bancroft T, Cao F: Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens 2013, 7(1):46-60.
• [22]Antihypertensive Pill Burden & Patient Adherence. Available from: http://www.physiciansweekly.com/ash-2014-antihypertensive-pill-burden-adherence/.
• [23]Zyoud SH, Al-Jabi SW, Sweileh WM, Wildali AH, Saleem HM, Aysa HA, et al.: Health-related quality of life associated with treatment adherence in patients with hypertension: a cross-sectional study. Int J Cardiol 2013, 168(3):2981-3.
• [24]DiMatteo MR, Giordani PJ, Lepper HSCT: Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002, 40(9):794-811.
• [25]Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al.: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155(4):772-9.
• [26]Szende A, Janssen B, Cabases J. Self-Reported Population Health: An International Perspective based on EQ-5D. Szende A, Janssen B, Cabases J, editors. Dordrecht: Springer Netherlands; 2014. Available from: http://link.springer.com/10.1007/978-94-007-7596-1.
• [27]Whynes DK: Does the correspondence between EQ-5D health state description and VAS score vary by medical condition? Health Qual Life Outcomes 2013, 11:155. BioMed Central Full Text
• [28]Maatouk I, Wild B, Herzog W, Wesche D, Schellberg D, Schöttker B, et al.: Longitudinal predictors of health-related quality of life in middle-aged and older adults with hypertension: results of a population-based study. J Hypertens 2012, 30(7):1364-72.
• [29]Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al.: Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008, 43(1 Pt 1):327-39.